The National Health Insurance Authority (NHIA) in Nigeria has introduced measures to reduce the financial burden of cancer treatment on patients and their families. As part of these efforts, the authority has expanded insurance support for cancer treatment. This move aims to provide meaningful financial protection against high-cost illnesses. The NHIA's initiatives include an arrangement that shields eligible patients from 80 per cent of the cost of selected cancer medicines.
The expanded cost-sharing partnership between the NHIA and pharmaceutical company Roche is a key aspect of this initiative. Under this partnership, Roche bears 50 per cent of the cost of selected oncology medicines, while the NHIA contributes 30 per cent and eligible patients pay the remaining 20 per cent. This arrangement effectively covers 80 per cent of the cost of the selected medicines for beneficiaries. The NHIA has also introduced additional financial support ranging from N400,000 to full coverage for eligible radiotherapy patients.
The NHIA's interventions aim to ensure that health insurance offers meaningful financial protection against high-cost illnesses. The authority's Director-General, Dr Kelechi Ohiri, emphasized that the critical measure of the insurance system should no longer be the number of Nigerians carrying insurance records, but whether those records provide meaningful protection when illness strikes. The NHIA's measures are particularly important given the scale of Nigeria's cancer burden and the high out-of-pocket expenditure associated with treatment.
Nigeria records an estimated 32,278 new breast cancer cases and 16,332 deaths from the disease annually. Breast cancer remains the most commonly diagnosed cancer among Nigerian women and one of the leading causes of cancer deaths in the country. The NHIA cited figures from the Global Cancer Observatory to highlight the country's cancer burden. The authority also noted that treatment costs could expose families to prolonged financial pressure, particularly because advanced treatment abroad is beyond the reach of most Nigerians.
The NHIA's initiatives complement the Federal Government's broader cancer prevention and treatment programme under the Federal Ministry of Health and Social Welfare. Nigeria is implementing the National Cancer Control Plan 2026–2030, which covers prevention, early detection, diagnosis, treatment, patient navigation, survivorship, research, data management, and expansion of the oncology workforce. The government is also upgrading six Oncology Centres of Excellence across the country, with centres at the University College Hospital, Ibadan, and University of Benin Teaching Hospital, Benin, already fully operational.
The NHIA acknowledged that the interventions are not sufficient to address the country's cancer burden. The authority urged women to pay close attention to changes in their breasts, seek medical advice promptly, and take advantage of screening opportunities where available. Reducing deaths and financial hardship from breast cancer will require stronger public awareness, earlier diagnosis, wider access to treatment, and financing mechanisms capable of preventing illness from pushing households into financial distress.
More than 23 million Nigerians are currently enrolled in the national health insurance system, according to the NHIA. The expanding pool provides a platform for extending interventions for cancer and other high-cost diseases. The authority's interventions also include the Cancer Access Partnership programme, which provides 27 anti-cancer medicines in 48 formulations across 14 federal tertiary hospitals, and the Cancer Health Fund for indigent patients with breast, cervical, and prostate cancers.
Key points
- The NHIA has expanded insurance support for cancer treatment to reduce the financial burden on patients and families.
- The authority's initiatives include an arrangement that shields eligible patients from 80 per cent of the cost of selected cancer medicines.
- Nigeria records an estimated 32,278 new breast cancer cases and 16,332 deaths from the disease annually.
